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Abstract
Analysis of anticancer immunity aids in assessing the prognosis of patients with 
breast cancer. From 250 operated breast cancers, we focused on serum levels of 
C-C motif chemokine ligand 5 (CCL5), which is involved in cancer immune reactions. 
Serum levels of CCL5 were measured using a cytometric bead-based immunoassay 
kit and CCL5 expression in cancer cells was determined using immunohistochemical 
staining. In addition, mRNA in cancer and stromal cells was analyzed by microdissec-
tion and comparison with the public dataset. Disease-free survival (DFS) of patients 
with high CCL5 levels (cut-off, 13.87 ng/mL; n = 192) was significantly better than 
those with low CCL5 levels (n = 58; hazard ratio, 0.20; 95% confidence interval, 0.10-
0.39; P < .0001). An improved overall survival was observed in patients with high 
CCL5 levels compared to those with low CCL5 levels (P = .024). On the contrary, high 
immunohistochemical expression of CCL5 in cancer cells was significantly associated 
with decreased DFS. As serum CCL5 levels did not correlate with CCL5 expression 
in cancer cells and the relative expression of mRNA CCL5 was elevated in stromal 
cells in relation to cancer cells, serum CCL5 might be derived not from cancer cells, 
but from stromal cells. Expression of CCL5 in serum, but not in cancer cells, might 
contribute to improved patient prognosis mediating through not only immune reac-
tion, but through other mechanisms. Determination of circulating CCL5 levels could 
be useful for predicting patient prognosis.
K E Y W O R D S
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1  | INTRODUC TION
Recently, the involvement of immune reactions became well es-
tablished in the initiation and progression of breast cancers.1-3 In 
particular, positive associations between high levels of TILs and fa-
vorable prognoses have been repeatedly confirmed by many stud-
ies.4-6 In a metaanalysis consisting of 22 964 patients, the DFS and 
OS of patients with TN breast cancers with high numbers of TILs 
were significantly better than those with few TILs (for DFS: HR, 
0.82; 95% CI, 0.76-0.88; for OS: HR, 0.79; 95% CI, 0.71-0.87).6 In 
addition to TILs, the NLR in the blood has been reported to be a 
prognostic indicator of early breast cancers.7,8 Similar to TILs, pa-
tients with low levels of NLR, which indicate relatively more lym-
phocytes than neutrophils, are associated with a significantly better 
prognosis than patients with high NLRs (for DFS: HR, 1.47; 95% CI, 
1.06-2.05; P = .025; for OS: HR, 2.21; 95% CI, 1.99-4.11; P = .001).7
These data strongly indicate immunity against breast cancers 
is critical in terms of prognosis during the course of treatment of 
patients. However, the application of these biomarkers has been 
limited. Although elevated TIL numbers represent a T cell immune 
reaction, it is not known whether the function of these T cells is 
induced or suppressed by several factors, such as Tregs, MDSCs, 
tumor-associated macrophages, or unfavorable cancer microenvi-
ronment.9,10 Furthermore, the prognostic significance of the NLR is 
still controversial.11 Interestingly, positive associations between a 
high NLR and increased levels of circulating cytokines, including IL-6, 
IL-8, IL-2Rα, hepatocyte growth factor, macrophage-colony stimulat-
ing factor, and vascular epidermal growth factor, have been reported 
in metastatic colorectal cancers.12 As these inflammatory cytokines 
might be linked with anticancer immune responses, the NLR is spec-
ulated to be associated with patient prognosis by mediating through 
these cytokines.
C-C motif chemokine ligand 5 is a chemokine produced by T 
lymphocytes, platelets, endothelial cells, macrophages, mono-
cytes, NK cells, and DCs.13-16 In addition, CCL5 secretion from 
mesenchymal stem cells and breast cancer cells are reported.17-19 
It was found that CCL5 promotes breast cancer metastasis in a 
paracrine fashion, including enhancement of breast cancer motil-
ity, invasion, and metastatic ability.17 In addition, CCL5 promotes 
breast cancer metastasis by maintaining the immunosuppressive 
ability of MDSCs.20 Furthermore, a positive association between 
CCL5 and an aggressive phenotype or metastatic potential has 
been reported for breast cancer.21,22 Therefore, CCL5 promotion 
of breast cancer progression and metastasis has been the focus of 
many studies 23.
Supporting these in vitro and in vivo studies, high levels of 
CCL5 in patients with gastric cancer are associated with poor 
prognoses.24 Based on quantum-dot-based molecular imaging, 
high expression of CCL5 is significantly associated with poor DFS 
(P = .001) in patients with luminal B and HER2-negative breast 
cancers.25 However, contrary to these studies, high CCL5 gene 
expression is significantly associated with good RFS in patients 
with TN breast cancer (HR, 0.39; 95% CI, 0.22-0.71; P = .0012).26 
Therefore, the prognostic significance of CCL5 in early breast can-
cers remains unclear.
In the present study, we examined serum CCL5 levels in terms of 
prognostic significance in patients with early breast cancer focusing 
on breast cancer subtypes. In addition, immunohistochemical stain-
ing of CCL5 in cancer cells and the relationship between serum CCL5 
levels and TILs were evaluated.
2  | MATERIAL S AND METHODS
2.1 | Patient recruitment
Patients with breast cancer operated on at the Hyogo College of 
Medicine Hospital between July 2009 and November 2016 were 
consecutively recruited for this retrospective study. During this pe-
riod, 792 female patients were pathologically diagnosed with primary 
invasive breast carcinoma. We obtained informed consent for this 
study from 695 patients. Of these patients, 250 participants with 
enough volume of serum samples and that were available for this 
study were recruited. In addition, serum samples from noninvasive 
breast cancers (n = 29) and metastatic breast cancers (n = 49) were 
also analyzed. This study was approved by the ethics committee of the 
Hyogo College of Medicine (No. 106) and was in accordance with the 
Declaration of Helsinki. Written informed consent was obtained from 
each patient. Data on individual participants are unavailable because 
the Institute's ethics committee did not permit their publication.
2.2 | Adjuvant treatments and patient follow-up
Chemotherapies were given preoperatively (n = 12), postoperatively 
(n = 56), and both (n = 3). These included anthracycline-containing 
(n = 5), taxane-based (n = 24), sequential use of anthracycline and 
taxanes, (n = 38), and other (n = 4) chemotherapy regimens. A total of 
184 patients were treated with endocrine therapies, including lutein-
izing hormone-releasing hormone plus tamoxifen (n = 37), tamoxifen 
(n = 18), and aromatase inhibitors (n = 115). Endocrine therapies were 
switched from luteinizing hormone-releasing hormone plus tamox-
ifen to aromatase inhibitors (n = 5) or luteinizing hormone-releasing 
hormone plus aromatase inhibitors (n = 3), tamoxifen to aromatase 
inhibitors (n = 1), aromatase inhibitors to tamoxifen (n = 2) or lutein-
izing hormone-releasing hormone plus tamoxifen (n = 1), and others 
(n = 2). Trastuzumab was used in 19 of 30 HER2-positive cases.
The vast majority of the patients visited the hospital postopera-
tively every 3 to 6 months for 3 years and then every 6 to 12 months 
thereafter. The median follow-up time was 45.7 months (range, 0.6-
101.2 months). During follow-up, 29 patients had recurrence that 
was locoregional and in the lymph nodes (n = 10), ipsilateral or con-
tralateral breast (n = 2), bone (n = 11), lungs (n = 6), liver (n = 2), or 
pleura (n = 2). Disease-free survival was defined as the time from 
the operation to the first recurrence at any site, contralateral breast 
cancer, or death for any reason.
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2.3 | Measurements of serum CCL5
Blood samples were obtained on the same day of the operation and 
just before the start of the operation. For the 15 patients treated with 
preoperative chemotherapies, blood samples were collected before 
the start of these treatments. Serum levels of CCL5 were measured 
using a cytometric bead-based immunoassay kit according to the 
manufacturer's protocol (Human RANTES Flex Set; BD Biosciences). 
Briefly, capture bead populations with distinct fluorescence intensities 
and coated with RANTES-specific capture Ab were mixed together in 
equal volumes, where 50 μL of each sample and 50 μL of phycoeryth-
rin-conjugated detection Ab was added to 50 μL of a mixed-bead pop-
ulation. This mixture was incubated for 3 hours at room temperature 
in the dark to form sandwich complexes. The beads were then washed 
with wash buffer and analyzed with a BD LSRFortessa X-20 cell ana-
lyzer and FCAP Array software (BD Biosciences).
2.4 | Immunohistochemical staining of CCL5, 
CD8, and FOXP3
From 250 patients, 160 breast cancer tissues were obtained for 
immunohistochemical staining of CCL5, in which adequate cancer 
cells were included. In addition, we were able to evaluate CD8 and 
FOXP3 expression levels in 156 and 143 samples, respectively. 
These samples were obtained during operation or biopsy prior to 
preoperative therapies. Formalin-fixed, paraffin-embedded tumor 
tissues were cut and deparaffinized, then antigen was retrieved 
for 8 minutes using a Cell Conditioning Solution (CC1; Ventana 
Medical Systems). Primary Ab (anti-RANTES Ab, ab9679, rabbit 
polyclonal antibody; Abcam) was diluted to 1:100. We used an 
anti-CD8 primary Ab (CONFIRM anti-CD8 SP57 rabbit mAb; Roche 
Diagnostics) without dilution and 236A/E7 Ab (ab20034, mouse 
mAb; Abcam) against FOXP3 diluted to 1:500. The procedure was 
carried out in an automated immunostainer Ventana BenchMark 
ULTRA using the I-VIEW DAB universal kit (Roche Diagnostics) 
for CCL5 and CD8, and in automated immunostainer BOND-
MAX using the Bond PolymerRefine kit (Leica Microsystems) for 
FOXP3. We used human skeletal muscle cells and normal breast 
epithelial cells as positive and negative controls, respectively, for 
CCL5. Positive controls for CD8 and FOXP3 were lymph node and 
tonsil cells, respectively, and normal breast epithelial cells were 
used as negative control. We evaluated cytoplasmic staining of 
cancer cells for CCL5, membrane staining of lymphocytes for CD8, 
and nuclear staining of lymphocytes for FOXP3. More than 500 
cancer cells were counted in the areas of the stained lesions and 
the proportion of positive cells was calculated for CCL5. As for 
CD8 and FOXP3, positive cells were counted at a ×400 field and 
average counts of 4 fields were obtained.
We used the median value of 20% CCL5-positive cells as a cut-
off value for DFS and divided breast cancers into CCL5-high (>20%, 
n = 71) and CCL5-low (≤ 20%, n = 89) groups. In order to compare 
cellular CCL5 levels with those in serum, cells were divided into 4 
groups: 0% cancer-positive cells and 3 groups with equal numbers of 
patients for 1% or more positive cancer cells (1%-49%, n = 33; 50%-
69%, n = 29; 70% or more, n = 25).
2.5 | Evaluation of TILs
Tumor-infiltrating lymphocytes in breast cancer biopsy specimens 
treated with preoperative therapy (n = 13) and surgical specimens 
not exposed to preoperative therapy (n = 196) were measured ac-
cording to a method described in a previous study.27 Briefly, lympho-
cytes and plasma cells within the tumor border were counted as TILs 
in a medium-power field (×100) in the hot spot area. We classified 
TIL scores as low (less than 50%) or high (50% or more).
2.6 | Public database
We calculated RFS and OS according to CCL5 gene expression levels 
provided by gene chip data using a specific probe (Affymetrix ID, 
1555759_a_at) through the Kaplan-Meier Plotter database (http://
kmplot.com/analy sis/).28 In this dataset, a total number of 1764 
breast cancers was included and we used the median as a cut-off 
value. Spearman’s correlations between the mRNA levels of CCL5 
and of other genes were determined using cBioPortal (http://www.
cbiop ortal.org/)29,30 for 1084 invasive breast carcinoma samples 
(The Cancer Genome Atlas, PanCancer Atlas). Network analysis 
of CCL5 was done using the public database on cBioPortal (http://
www.cbiop ortal.org/). CCL5 expression in microdissected breast 
tumor cells and normal breast ductal cells was analyzed using micro-
array data (GSE38959).31 In order to compare CCL5 mRNA expres-
sion levels between laser capture microdissected cancer cells and 
stromal cells, we used public dataset, GSE31192, including breast 
cancers from pregnant and nonpregnant women (CCL5 probe no. 
1555759_a_at).32
2.7 | Statistical analysis
The relationships between the clinicopathological characteristics 
and serum CCL5 levels were compared using Fisher’s exact test 
or the Wilcoxon rank-sum test. Differences in DFS in different 
subgroups were calculated using Kaplan-Meier plots and log-rank 
tests. A Cox proportional hazards model was used to obtain HRs 
and 95% CIs for univariable and multivariable analyses of clinical 
factors and CCL5 levels for DFS. Serum levels of CCL5 were com-
pared among subgroups according to TIL levels or breast cancer 
types (noninvasive, invasive, or metastatic) using the Wilcoxon 
rank-sum test. Statistical significance was set at P < .05 except 
for multiple CCL5 comparisons adjusted with the Bonferroni cor-
rection, for which significance was set at P < .0083 or P < .017. All 
statistical calculations were undertaken using JMP Pro 13 (SAS 
Institute).
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3  | RESULTS
3.1 | Determination of serum CCL5 in noninvasive, 
invasive, and metastatic breast cancers and 
determination of the cut-off value for DFS
The median value of CCL5 serum levels in invasive cancer of 
32.90 ng/mL (range, 1.75-646.64 ng/mL) was similar to the results 
obtained in noninvasive cancers (median, 31.39; range, 7.47-102.68; 
P = .909), but significantly lower than those from metastatic can-
cers (median, 62.96; range, 5.60-169.44; P < .0001, Figure S1). We 
determined the cut-off value of CCL5 in invasive breast cancers to 
be 13.87 ng/mL for DFS based on receiver operating characteristic 
curves calculated as 0.676 using the Youden index for area under 
the curve as shown in Figure S2 (P = .0069). Using this cut-off, we 
divided patients into CCL5-high (n = 192) and -low (n = 58) (Table 1).
3.2 | Relationship between clinicopathological 
characteristics and serum CCL5 levels
Clinicopathological factors in CCL5-high and -low cohorts were 
compared in Table 1. Patients in CCL5-high cancers were signifi-
cantly younger than those in the CCL5-low group (median age, 58 vs 
68 years; P = .0009) and CCL5-high breast cancers significantly fre-
quently had a small tumor size (P = .0495) and HER2-negative status 
(P = .0178). There were no significant differences for other factors 
between CCL5-high and -low breast cancers.
3.3 | Disease-free survival of patients according to 
serum CCL5 levels
The DFS of CCL5-high patients was significantly better than for 
those that were CCL5-low (4-year DFS, 0.93 and 0.61, respectively; 
HR, 0.20; 95% CI, 0.10-0.39; P < .0001; Figure 1). Similarly, there 
was a significant difference in the OS of CCL5-high and -low patients 
(P = .024; Figure 1). In the subgroup analysis, CCL5-high patients 
consistently had a better DFS than CCL5-low patients, irrespective 
of subgroup (Figure S3).
3.4 | Univariable and multivariable analyses of 
prognostic factors of DFS, including CCL5 levels
Univariable analysis showed that menopausal status (P = .0380), 
tumor size (P = .0234), lymph node metastasis (P = .0001), tumor 
grade (P = .0024), Ki67 expression levels (P = .0017), CCL5 levels 
(P < .0001), and immunohistochemical staining of CCL5 (P = .0246) 
were significant prognostic factors for DFS (Table 2). We confirmed 
that serum CCL5 levels (HR, 0.28; 95% CI, 0.11-0.70; P = .0068) was 
independent and significant prognostic factors for DFS as it was sig-
nificant in the multivariable analysis (Table 2).
TA B L E  1   Clinicopathological characteristics of breast cancers 





(n = 58) P-valuec 
Age, years; median 
(range)
58 (28-86) 68 (34-90) .0009
Menopausal status
Pre- 67 (83.8)a  13 (16.3) .0786
Post- 124 (73.4) 45 (26.6)
Otherd 1 (100.0) 0 (0.0)
Tumor size, cm
≤2 141 (80.6) 34 (19.4) .0495
>2 51 (68.9) 23 (31.1)
Unknown 0 (0.0) 1 (100.0)
Lymph node metastasis
Negative 146 (79.8) 37 (20.2) .0825
Positive 43 (68.3) 20 (31.8)
Not examined 3 (75.0) 1 (25.0)
No. of lymph node metastases
0 146 (79.8) 37 (20.2) .349
1-3 24 (66.7) 12 (33.3)
4-9 11 (68.8) 5 (31.3)
10 and more 8 (72.7) 3 (27.3)
Not examined 3 (75.0) 1 (25.0)
Tumor grade
1 115 (77.2) 34 (22.8) .7435
2 + 3 65 (79.3) 17 (20.7)
Unknown 12 (63.2) 7 (36.8)
Estrogen receptor
Positive 162 (78.6) 44 (21.4) .1676
Negative 30 (68.2) 14 (31.8)
HER2 status
Negative 175 (79.6) 45 (20.5) .0178
Positive 17 (58.6) 12 (41.4)
Unknown 0 (0.0) 1 (100.0)
Ki67 expression levele
Low 102 (78.5) 28 (21.5) 1.0000
High 87 (78.4) 24 (21.6)
Unknown 3 (33.3) 6 (66.7)
Chemotherapy treatment
No 134 (75.3) 44 (24.7) .5068
Yes 57 (80.3) 14 (19.7)
Unknown 1 (100.0) 0 (0.0)
Abbreviation: HER2, human epidermal growth factor receptor 2.
aData are shown as n (%) unless otherwise indicated. 
bHigh: ≥ 13.87 ng/mL, low: < 13.87 ng/mL. 
cFischer’s exact test (unknown cases were excluded.). 
dMale breast cancer patient 
eLow: < 20%, high: ≥ 20%. 
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3.5 | Disease-free and overall survival of patients 
according to immunohistochemical expression of 
CCL5 levels in cancer cells
Positive staining of cytoplasm in invasive cancer cells by im-
mune staining was evaluated as shown in Figure S4. Disease-
free survival of patients with CCL5-high breast cancers (n = 71) 
was significantly worse than those with CCL5-low breast can-
cers (n = 89) (P = .0194) (Figure 2). There was no significant dif-
ference in OS between CCL5-high and -low patients (P = .1441) 
(Figure 2).
3.6 | Correlations between serum CCL5 and 
immunohistochemical expression of CCL5 or 
TIL levels
There was no significant difference between serum levels of 
CCL5 and immunohistochemical staining of CCL5 in cancer 
cells separated by the 20% cut-off value (P = .502; Figure 3). 
According to the further division of CCL5 immunohistochemical 
staining into 4 groups based on expression levels (0%, 1%-49%, 
50%-69%, and 70% or higher), serum CCL5 levels in immunohis-
tochemical CCL5-positive groups (1% and above) were not sig-
nificantly different when compared with the CCL5-negative (0%) 
group (Figure 3).
Serum levels of CCL5 and immunohistochemical staining of 
CCL5 in cancer cells did not differ between TIL-high and -low pa-
tients when all patients were considered (P = .257 or P = .427, Table 
S1). However, the frequency of patients with high serum levels of 
CCL5 was significantly higher in the TIL-high group exclusively in 
the TN subtype. Furthermore, the CD8+ cells, FOXP3+ cells, or 
the FOXP3/CD8 ratio did not significantly associate with serum 
CCL5 levels. Both CD8+ cells and FOXP3+ cells were marginally 
increased in CCL5+ cancers (P = .0787 and P = .0769, respectively), 
but the FOXP3/CD8 ratio did not differ between CCL5+ and CCL5− 
cancers (P = .1625).
3.7 | Associations of CCL5 gene expression levels 
with outcome and gene networks related to CCL5 
in the public dataset
Using the Kaplan-Meier Plotter public mRNA expression dataset, 
the prognostic significance of CCL5 mRNA expression was analyzed. 
Both the RFS and OS of patients with high CCL5 gene expression 
were significantly better than in patients with low CCL5 gene expres-
sion divided by the median value (Figure 4). Next, network analysis 
of CCL5 was carried out using the cBioPortal software. As shown in 
Figure 5, GNA11, GNB2, GNB4, GNG13, GNGT1, GRK6, SDC4, MYC, 
and MAX were found to be directly connected with CCL5. In addition, 
Spearman’s correlations and P-values of correlated genes are listed in 
Table S2. GRK6, GNB4, MAX, MYC, and GNGT1 were significantly and 
positively associated with CCL5. On the contrary, GNGA11, GNG13, 
and SDC4 were significantly connected to CCL5 in a negative manner.
3.8 | CCL5 mRNA expression levels in cancer and 
stromal cells
The mRNA expression levels of CCL5 were determined in normal breast 
tissue and in breast cancer tissues separated by laser capture microdis-
section considering 30 TN breast cancers in the public dataset. The rela-
tive expression levels of CCL5 were not significantly different between 
normal breast and breast cancer tissues (P = .079, Figure S5A). Next, we 
evaluated CCL5 expression levels in breast cancer tissues that were sepa-
rated using the microdissection method into stromal cells and cancer cells 
regarding the public dataset including breast cancers from pregnant and 
nonpregnant patients. Expression levels of CCL5 in stromal cells were sig-
nificantly higher than those in cancer cells (P = .0064) (Figure S5B).
4  | DISCUSSION
In the present study, we found that the DFS of patients with high 
levels of CCL5 at baseline was significantly better than in those with 
F I G U R E  1   Disease-free survival (A) 
and overall survival (B) of breast cancer 
patients with high and low serum C-C 
motif chemokine ligand 5 (CCL5) levels 
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low CCL5. This significant association between CCL5 and prog-
nosis seems to be consistent irrespective of subtypes. It has been 
reported that β-catenin induction results in an aggressive CCL5-
mediated phenotype in breast cancer that displays increased cell 
invasion and spheroid formation in breast cancer cells.33 Similarly, 
cooperative induction of CCL5 and IL-6 induces an aggressive phe-
notype in breast cancer cells.22 Based on these studies, CCL5 has a 
direct role in the progression and metastasis of breast cancers. In 
line with these results, a poor patient prognosis is associated with 
high expression of CCL5 in breast cancers as determined by quanti-
tative protein analysis.25 We identified a worse prognosis of patients 
with high expression of CCL5 in cancer cells, as determined by im-
munohistochemical staining. Contrary to these results, patients with 
high serum levels of CCL5 had a significantly improved DFS. The 
latter result was further supported by previous studies26,33 as well 
as by the results obtained from the analysis of the public dataset 
presented in this study.
As mentioned above, it is speculated that CCL5 expressed in 
breast cancer cells might contribute to progression and enhance 
metastatic potential. However, Jayasinghe et al18 reported that tu-
mor-derived CCL5 had no impact on breast cancer growth rate or 
metastatic ability. In addition to cancer cells, CCL5 is derived from 
 n
Univariable 
analysis HR (95% 
CI) P-value
Multivariable analysis 
HR (95% CI) P-value
Menopausal status
Pre- 80 1.00 .0380 1.00 .0835
Post- 169 2.37 (1.05-6.34) 2.59 (0.89-9.48)
Tumor size, cm
≤2 175 1.00 .0234 1.00 .7561
>2 74 2.29 (1.12-4.56) 1.17 (0.41-3.13)
Lymph node metastasis
Negative 183 1.00 .0001 1.00 .4570
Positive 63 4.11 (2.02-8.48) 1.47 (0.53-4.12)
Tumor grade
1 149 1.00 .0024 1.00 .7291
2 + 3 82 2.97 (1.48-6.08) 1.21 (0.42-3.86)
Estrogen receptor status
Positive 206 1.00 .1581   
Negative 44 1.78 (0.78-3.71)   
HER2 status
Negative 220 1.00 .1148   
Positive 29 2.06 (0.82-4.51)   
Ki67 expression levela
Low 130 1.00 .0017 1.00 .1067
High 111 3.10 (1.51-6.82) 2.76 (0.80-9.71)
CCL5 levelb
Low 58 1.00 <.0001 1.00 .0068
High 192 0.20 (0.10-0.39) 0.28 (0.11-0.70)
Immunohistochemical staining of CCL5c
Low 89 1.00 .0246 1.00 .1741
High 71 2.68 (1.14-6.44) 1.89 (0.75-4.88)
Chemotherapy treatment
No 178 1.00 .1924   
Yes 71 1.62 (0.77-3.26)   
Abbreviations: CCL5, C-C motif chemokine ligand 5; CI, confidence interval; HER2, human 
epidermal growth factor receptor 2; HR, hazard ratio.
aLow, <20%; high, ≥20%. 
bHigh, ≥13.87 ng/mL; low, <13.87 ng/mL. 
cLow: ≤20%, high >20%. 
TA B L E  2   Univariable and multivariable 
analyses of disease-free survival among 
breast cancer patients
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F I G U R E  2   Disease-free survival (A) 
and overall survival (B) of breast cancer 
patients according to the proportion of 
positive immunohistochemical staining 
of C-C motif chemokine ligand 5 (CCL5) 
(high, >20%; low, ≤20%)
F I G U R E  3   Correlation between serum 
C-C motif chemokine ligand 5 (CCL5) 
levels and immunohistochemical staining 
of CCL5 in cancer cells. Positive cells were 
divided into (A) ≤20% (n = 89) or >20% 
(n = 71), and (B) 0% (n = 73), 1%-49% 
(n = 33), 50%-69% (n = 29), or ≥70% 
(n = 25)
F I G U R E  4   Relapse-free survival (RFS) 
(A) and overall survival (OS) (B) of breast 
cancer patients according to CCL5 gene 
expression levels in the public dataset. 
Cut-off value was set to the median value
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mesenchymal stem cells17 and peritumoral adipose tissue.34 As 
CCL5 is a chemokine, several functions associated with the immune 
reaction generated from cells other than cancer cells might also be 
involved in cancer progression and, thus, influence poor prognosis. 
It has been reported that CCL5 plays an important role mediating 
the migration of several sets of immune cells, including T lympho-
cytes, monocytes, eosinophils, NK cells, and macrophages.35,36 In 
ER-positive breast cancer, CCL5 increases infiltration of tumor-as-
sociated macrophages.37 Furthermore, CCL5 leads to polarization of 
CD4+ cells into an immunosuppressive Th2 phenotype, which pro-
motes metastasis in luminal breast cancer.38
In contrast to these immunosuppressive effects, CCL5 also in-
creases migration and recruitment of lymphocytes into tumors. 
Upregulation of CCL5 induction as a result of microRNA-21 inhibi-
tion promotes lymphocyte migration in MCF-7 breast cancer cells.39 
Considering that infiltration of CD8+ effector T cells into inflamed 
melanoma tissues depends on chemokines, including CCL5,40 
CCL5 could play a role in immune-mediated tumor regression. 
Furthermore, intratumoral injection of interferon-beta induces the 
expression of CCL5 in melanoma and leads to the recruitment of 
CD8+ T cells.41 Recently, Araujo et al26 reported that high expression 
of CCL5 is associated with recruitment of CD8+ T cells, including ex-
pressions of CD8A and CD8B, activated CD4+ T cells, activated NK 
cells, and M1 macrophages. These results suggest the antitumor ef-
fects of CCL5 were induced by T cell-mediated immunity. In line with 
this speculation, a positive correlation between CCL5 and TIL count 
was observed (P = .003).26 Interestingly, TIL count, but not CCL5 ex-
pression, was a significant and independent factor for distant RFS 
(HR, 0.336; 95% CI, 0.150-0.753; P = .008) in a multivariable analy-
sis, although both factors were significant in a univariable analysis.26
A positive association between CCL5 and TILs was consistent in 
the TN subtype but not in other subtypes in our study. The mecha-
nism for these discrepant results depending on subtypes is currently 
unknown. According to the TIL gene signature, factors related to 
good prognosis, including CD8+ T cells, B cells, M1 macrophages, 
and DCs, were mainly involved in ER-negative breast cancers.42 On 
the contrary, an abundance of molecules linked with poor prognosis, 
such as Tregs, MDSCs, and neutrophils, are related to ER-positive 
breast cancers. The differences in the immune microenvironment of 
TN and other subtypes might partly explain discrepant association 
results between CCL5 and TILs. However, as the prognostic signif-
icance of serum CCL5 levels was obtained in this study regardless 
of the cancer subtype, CCL5 might be associated with prognosis, at 
least partly, due to the mediation of functions other than immunity 
against breast cancers.
On the basis of network analysis, we determined a positive link 
between CCL5 and GNB4, GNGT1, GRK6, Myc, and MAX (Figure 5; 
Table S2). In addition, we have encountered a negative association 
between CCL5 and GNA11, GNG13, and SDC4. Umar et al reported 
that the prognosis of patients with high GNB4 levels was signifi-
cantly better than that of those with low levels in breast cancers 
treated with tamoxifen.43 In a mouse model, GRK6 deletion up-
regulated tumor-infiltrating polymorphonuclear leukocyte and mi-
crovessel density, resulting in tumor progression and metastasis.44 
In addition to the oncogenic function of Max in cooperation with 
Myc, MAX and the mitotic arrest deficient (Mad) network have 
been shown to antagonize Myc function through the mediation 
of proliferation, differentiation, and apoptosis.45 According to the 
Kaplan-Meier Plotter database, high levels of Max, but not of Myc, 
are significantly associated with a better prognosis, which is con-
sistent with CCL5 (data not shown), thus Max might contribute to 
favorable breast cancer prognosis. Additionally, SDC4 has been re-
ported to promote transforming growth factor-β1-induced epithelial 
to mesenchymal transition in lung adenocarcinoma cells46 and the 
upregulation of GNA11 in metastatic cancers when compared with 
primary TN breast cancers.47 As the mRNA expression of SDC4 and 
GNA11 is negatively associated with CCL5, these studies could be 
in line with a good prognosis of CCL5-high breast cancers mediated 
through low SDC4 and GNA11. This, CCL5 could contribute for the 
progression of breast cancers in cooperation with these molecules. 
The precise mechanisms underlying the prognostic significance of 
CCL5 remain to be determined, although multifunctional effects, in-
cluding immune reactions and other functions mentioned above, are 
speculated to be involved.
Both expression of CCL5 in cancer cells and serum levels of 
CCL5 were linked with prognosis, but mediated through different 
mechanisms; based on multivariable analysis, expression of CCL5 
in serum but not in cancer cells was found to be a significant and 
independent prognostic factor (Table 2). As serum levels of CCL5 
in invasive breast cancers were lower than those in metastatic 
F I G U R E  5   Schematic representation 
of network genes correlated with CCL5 
in the cBioPortal (http://www.cbiop ortal.
org/)
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breast cancers (Figure S1), we speculate that CCL5 serum levels 
are not due to nonspecific inflammation, but to a cancer-specific 
reaction. As shown in Figure 3, there was no significant association 
between the immunohistochemical expression of CCL5 in cancer 
cells and serum CCL5 levels. Even in breast cancer cells with no 
CCL5 expression, the serum CCL5 levels were similar to those in 
CCL5-positive cancers. Furthermore, according to the samples 
analyzed by microdissection, mRNA expression levels of CCL5 in 
stromal cells were significantly higher when compared to those in 
cancer cells (Figure S5). Considering these results, we believe the 
great majority of serum CCL5 was derived not from cancer cells, 
but from stromal cells. The mRNA expression levels from the pub-
lic database shown in Figure 4 might include both cancer and stro-
mal cells; a positive association between CCL5 and prognosis was 
consistent with serum CCL5, but not with the immunohistochem-
ical expression of CCL5 in cancer cells. Accordingly, evaluation of 
total CCL5 levels in the blood, including production by both cancer 
cells and other tissues, appears to be superior to examination of 
expression in cancer cells. To the best of our knowledge, this is the 
first study to reveal the prognostic significance of serum levels of 
CCL5 in breast cancers. The limitation of this study is that we were 
unable to determine a direct association between serum CCL5 and 
expression in stromal cells because most of the paraffin-embed-
ded tumor samples contained mainly cancer cells and inadequate 
stromal cells, especially in surrounding areas, and detailed analy-
sis in stromal cells is infeasible. In addition, the functional mech-
anisms of CCL5 in favorable prognosis remain unsolved. These 
issues need to be addressed in future studies evaluating a larger 
sample population.
We showed that high serum CCL5 levels were significantly asso-
ciated with improved prognosis of patients with early breast cancer. 
CCL5 could be associated with prognosis through multiple effects 
involving immune reactions and other factors. These data might be 
useful for predicting patient prognosis in clinical practice.
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